NCT02754817View on ClinicalTrials.gov

A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

611

Participants

Timeline

Start Date

April 26, 2016

Primary Completion Date

October 20, 2016

Study Completion Date

October 20, 2016

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin degludec/liraglutide

This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.

Trial Locations (5)

1130

Novo Nordisk Investigational Site, Vienna

9016

Novo Nordisk Investigational Site, Sankt Gallen

04103

Novo Nordisk Investigational Site, Leipzig

111 57

Novo Nordisk Investigational Site, Stockholm

SG1 4AB

Novo Nordisk Investigational Site, Stevenage

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY